Invitrogen™ Lirilumab Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Product Code	Brand	Quantity
30283929	Invitrogen™ MA558345	100 μg
30284260	Invitrogen™ MA558346	1 mg

Description

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

Lirilumab, also known as IPH2102 or BMS-986015, is a fully human IgG4 monoclonal antibody targeting inhibitory killer-cell immunoglobulin-like receptors (KIRs), notably KIR2DL1, KIR2DL2, and KIR2DL3, as well as activating KIR2DS1 and KIR2DS2. The structure of lirilumab includes the variable domains which bind to a conformational epitope on domain 1 of KIR2DL3. This binding does not significantly alter the structure of KIR2DL3 in comparison to its unbound form. Lirilumab's binding epitope overlaps with the HLA binding site, which influences the clinical efficacy of the drug as variations in this epitope among patients may impact its effectiveness. Functionally, lirilumab blocks inhibitory KIRs, thereby enhancing NK cell activity against tumor cells. This mechanism underlies its investigation in clinical trials for hematologic and solid malignancies, evaluating its efficacy both as a monotherapy and in combination with other agents such as azacitidine.

Specifications

• Antigen: Lirilumab
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Classification: Recombinant Monoclonal
• Form: Lyophilized
• Isotype: IgG4SP
• Target Species: Human
• Gene Alias: BMS-986015; IPH2102
• Product Type: Antibody

• Concentration: 1 mg/mL
• Applications: ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance
• Conjugate: Unconjugated
• Host Species: Human
• Regulatory Status: RUO
• Formulation: 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2
• Primary or Secondary: Primary
• Purification Method: Protein A